Indeed, following ACT therapy whereby gp100-specific CD8+ T cells are injected in mouse melanoma tumors, TNF production induces dedifferentiation processes leading to loss of melanocytic markers, decreased immunogenicity, and tumor relapse (23), phenomena which were recently observed in a melanoma patient treated with ACT (24) (Figure 1). Here, PMEL is linked to melanoma.